Herne

• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting
  2024-517284-23-00 5 2025-04-23 Active Psoriatic Arthritis
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting
  2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici … Recruiting
  2024-516219-25-00 5 2025-03-25 psoriatic arthritis
• Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis Recruiting
  2024-513213-13-00 6 2025-03-13 Axial Spondyloarthritis
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema … Recruiting
  2023-509146-35-00 6 2025-01-30 Systemic Lupus Erythematosus
• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting
  2023-504022-19-01 5 2024-12-13 Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex vir … Recruiting
  2023-504322-19-00 5 2024-01-10 Patients in the intensive care unit on ventilation with pneumonia and
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat … Recruiting
  2022-502851-79-00 5 2023-09-20 Active Idiopathic Inflammatory Myopathy (IIM)
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics … Recruiting
  2023-510061-10-00 3 2023-01-09 Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
• A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di … Recruiting
  2023-507518-28-00 5 2022-09-13 Acute myeloid leukemia
• Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, … Recruiting
  2024-512174-10-00 5 2021-11-11 metastatic colorectal cancer
• HIPEC/FLOT9 - PREVENT Recruiting
  2024-517300-10-01 5 2020-12-17 Resectable diffuse type gastric and gastroesophageal junction Typ II/I
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Ended recruitment
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• Effects of IL-23 inhibition in patients with very early axial spondyloarthritis – evidence for a true disease modification? Ended recruitment
  2023-507718-28-00 4 2024-12-19 AXIAL SPONDYLOARTHRITIS

Showing 49–72 of 133 trials